2. Cell Cycle/DNA Damage Antibody-drug Conjugate/ADC Related Anti-infection Autophagy Apoptosis
  3. Topoisomerase DNA/RNA Synthesis ADC Payload Bacterial Autophagy Apoptosis Antibiotic
  4. Daunorubicin hydrochloride

Daunorubicin hydrochloride  (Synonyms: Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride)

Cat. No.: HY-13062 Purity: 99.67%
COA
SDS
Handling Instructions Technical Support

Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 23541-50-6

사이즈 가격 재고 수량
무료 샘플 (0.1 - 0.2 mg)   지금 신청하기  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
5 mg 해외재고보유
10 mg 해외재고보유
25 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg 해외재고보유
500 mg 해외재고보유
1 g   견적 받기  
5 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 37 publication(s) in Google Scholar

Other Forms of Daunorubicin hydrochloride:

Daunorubicin hydrochloride Related Antibodies

Top Publications Citing Use of Products

37 Publications Citing Use of MCE Daunorubicin hydrochloride

Cell Proliferation/Viability Assay
Apoptosis Analysis
Cell Imaging/Staining

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Interdiscip Med. 2025 Sep 1;3(5):e70053.

    Cell viability analysis of OCI-AML2 cells expressing the indicated sgRNAs following treatment with increasing concentrations of Daunorubicin hydrochloride (3 days), assessed using the CCK-8 assay.

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Interdiscip Med. 2025 Sep 1;3(5):e70053.

    OCI-AML2 cells expressing indicated sgRNAs were treated with DMSO or Daunorubicin hydrochloride (10 nM), and viable cells were counted every 3–4 days.

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64.  [Abstract]

    Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Jul 6;20(1):304.  [Abstract]

    IC50 curves of Daunorubicin hydrochloride (1.25-1280 nM; 48 h) in U937 and Molm-13 cells transfected with lentivirus targeting SEMA4D or control. Transduced AML cells were treated with daunorubicin for 48 h and then measured by CCK-8 analysis.

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Jul 6;20(1):304.  [Abstract]

    Cell apoptosis rate of U937 and Molm-13 cells transfected with lentivirus targeting SEMA4D or control after Daunorubicin hydrochloride (10-80 nM) treatment was detected by flow cytometry using Annexin V-APC /PI staining.

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 May 5;13(5):661.

    Primary AML cells were treated with Daunorubicin hydrochloride (DNR, 8-32 μM) and Erastin (5 μM) for 48 h, and cell viability was assessed using the CCK-8 assay.

    Daunorubicin hydrochloride purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 May 5;13(5):661.

    HL-60 cells were pretreated with CCL20 for 30 min, followed by Daunorubicin hydrochloride (DNR, 1.6, 3.2 μM) treatment for 48 h, and lipid peroxidation level were measured.

    View All Topoisomerase Isoform Specific Products:

    View All Isoforms
    Topoisomerase Topo I Topo II DNA gyrase

    View All DNA/RNA Synthesis Isoform Specific Products:

    View All Isoforms
    RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

    View All ADC Payload Isoform Specific Products:

    View All Isoforms
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • 순도&문서

    • References

    • 고객리뷰

    제품 설명

    Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].

    IC50 & Target[1][2]

    Topoisomerase II

     

    Daunorubicins/Doxorubicins

     

    Cellular Effect
    Cell Line Type Value Description References
    A204 IC50
    3 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells
    Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells
    		10.1016/0960-894X(95)00523-3
    A498 IC50
    3 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells
    Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells
    		10.1016/0960-894X(95)00523-3
    CAPAN-1 IC50
    3.9 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against Capan-1 cell line (pancreatic carcinoma) after incubation for 24 hour
    Cytotoxicity of compound was tested against Capan-1 cell line (pancreatic carcinoma) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    CAPAN-1 IC50
    3.1 x 10-6 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against Capen-1 cell line (pancreatic carcinoma) after incubation for 72 hour
    Cytotoxicity of compound was tested against Capen-1 cell line (pancreatic carcinoma) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    CHO IC50
    2.94 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against CHO cell line (Chinese hamster ovary) after incubation for 72 hour
    Cytotoxicity of compound was tested against CHO cell line (Chinese hamster ovary) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    CHO IC50
    3.9 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against CHO cell line (Chinese hamster ovary) after incubation for 24 hour
    Cytotoxicity of compound was tested against CHO cell line (Chinese hamster ovary) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    EVSA-T IC50
    2 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against mammary carcinoma (EVSAT) human tumor cells
    Antiproliferative activity of compound was tested against mammary carcinoma (EVSAT) human tumor cells
    		10.1016/0960-894X(95)00523-3
    HCT-116 IC50
    0.28 μg/mL
    Compound: Daunorubicin HCl
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 12141872]
    HL-60 IC50
    < 9.8 x 10-8 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against HL-60 cell line (promyelocytic leukemia) after incubation for 24 hour
    Cytotoxicity of compound was tested against HL-60 cell line (promyelocytic leukemia) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    HL-60 IC50
    9.8 x 10-8 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against HL-60 cell line (promyelocytic leukemia) after incubation for 72 hour
    Cytotoxicity of compound was tested against HL-60 cell line (promyelocytic leukemia) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    HMEC IC50
    < 9.8 x 10-8 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against HMEC cell line (human mamm epithelial cells) after incubation for 72 hour
    Cytotoxicity of compound was tested against HMEC cell line (human mamm epithelial cells) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    HMEC IC50
    3.9 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against HMEC cell line (human mamm epithelial cells) after incubation for 24 hour
    Cytotoxicity of compound was tested against HMEC cell line (human mamm epithelial cells) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    HT-29 IC50
    0.072 μg/mL
    Compound: Daunorubicin HCl
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 12141872]
    HT-29 IC50
    3.57 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against HT-29 cell line (colon carcinoma) after incubation for 72 hour
    Cytotoxicity of compound was tested against HT-29 cell line (colon carcinoma) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    HT-29 IC50
    7.8 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against HT-29 cell line (colon carcinoma) after incubation for 24 hour
    Cytotoxicity of compound was tested against HT-29 cell line (colon carcinoma) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    HeLa IC50
    0.32 μM
    Compound: Daunorubicin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 17190447]
    IGROV-1 IC50
    18 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against ovarian carcinoma (IGROV) human tumor cells
    Antiproliferative activity of compound was tested against ovarian carcinoma (IGROV) human tumor cells
    		10.1016/0960-894X(95)00523-3
    K562 IC50
    0.015 μM
    Compound: DNR
    Cytotoxicity against drug-sensitive K562 cell line by MTS assay
    Cytotoxicity against drug-sensitive K562 cell line by MTS assay
    		[PMID: 16509594]
    K562 IC50
    156.6 μM
    Compound: DNR hydrochloride
    Cytotoxicity against K562 leukemia cell line done for 72 hr at 37 degree C with compound in MTS assay
    Cytotoxicity against K562 leukemia cell line done for 72 hr at 37 degree C with compound in MTS assay
    		[PMID: 16078845]
    K562 IC50
    > 5 μM
    Compound: DNR
    Cytotoxicity against doxorubicin-resistant K562 cell line by MTS assay
    Cytotoxicity against doxorubicin-resistant K562 cell line by MTS assay
    		[PMID: 16509594]
    L1210 ED50
    0.3 μM
    Compound: 1, daunorubicin
    Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation
    Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [3H]uridine incorporation
    		[PMID: 490537]
    L1210 ED50
    0.3 μM
    Compound: 2
    Inhibition of RNA synthesis in mouse L1210 cells
    Inhibition of RNA synthesis in mouse L1210 cells
    		[PMID: 423181]
    L1210 ED50
    0.3 μM
    Compound: 2
    Dose required to inhibit the RNA synthesis in leukemia L1210 cells
    Dose required to inhibit the RNA synthesis in leukemia L1210 cells
    		[PMID: 7252976]
    L1210 ED50
    0.33 μM
    Compound: 1 (Daunorubicin hydrochloride)
    Inhibition of [3H]uridine incorporation into proliferating L1210 cells.
    Inhibition of [3H]uridine incorporation into proliferating L1210 cells.
    		[PMID: 6716401]
    L1210 ED50
    0.4 μM
    Compound: 1, daunorubicin
    Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation
    Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]thymidine incorporation
    		[PMID: 490537]
    L1210 ED50
    0.66 μM
    Compound: 1 (Daunorubicin hydrochloride)
    Inhibition of [3H]thymidine incorporation into proliferating L1210 cells.
    Inhibition of [3H]thymidine incorporation into proliferating L1210 cells.
    		[PMID: 6716401]
    L1210 ED50
    1 μM
    Compound: 2
    Inhibition of DNA synthesis in mouse L1210 cells
    Inhibition of DNA synthesis in mouse L1210 cells
    		[PMID: 423181]
    L1210 ED50
    1 μM
    Compound: 2
    Dose required to inhibit the DNA synthesis in leukemia L1210 cells
    Dose required to inhibit the DNA synthesis in leukemia L1210 cells
    		[PMID: 7252976]
    L1210 (1565) IC50
    0.016 μM
    Compound: Daunomycin
    Cytotoxic activity against L-1210 parental cell line
    Cytotoxic activity against L-1210 parental cell line
    		10.1016/0960-894X(95)00067-4
    L1210 (1565) IC50
    0.147 μM
    Compound: Daunomycin
    Cytotoxic activity against adriamycin (ADR) resistant L-1210 cell line
    Cytotoxic activity against adriamycin (ADR) resistant L-1210 cell line
    		10.1016/0960-894X(95)00067-4
    LNCaP IC50
    0.011 μg/mL
    Compound: Daunorubicin HCl
    Cytotoxicity against human LNCAP cells expressing androgen receptor after 48 hrs by MTT assay
    Cytotoxicity against human LNCAP cells expressing androgen receptor after 48 hrs by MTT assay
    		[PMID: 12141872]
    M19-MEL IC50
    2 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against melanoma (M-19) human tumor cells
    Antiproliferative activity of compound was tested against melanoma (M-19) human tumor cells
    		10.1016/0960-894X(95)00523-3
    MCF7 IC50
    0.12 μg/mL
    Compound: Daunorubicin HCl
    Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
    		[PMID: 12141872]
    MCF7 IC50
    0.22 μM
    Compound: Daunorubicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 17190447]
    MCF7 IC50
    1.35 x 10-5 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against MCF-7 cell line (breast carcinoma) after incubation for 72 hour
    Cytotoxicity of compound was tested against MCF-7 cell line (breast carcinoma) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    MCF7 IC50
    2 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against mammary carcinoma (MCF-7) human tumor cells
    Antiproliferative activity of compound was tested against mammary carcinoma (MCF-7) human tumor cells
    		10.1016/0960-894X(95)00523-3
    MCF7 IC50
    7.8 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against MCF-7 cell line (breast carcinoma) after incubation for 24 hour
    Cytotoxicity of compound was tested against MCF-7 cell line (breast carcinoma) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    MDA-MB-231 IC50
    0.25 μM
    Compound: Daunorubicin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 17190447]
    MOLT-4 IC50
    8.55 x 10-13 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against Molt-4 cell line (T-cell leukemia) after incubation for 72 hour
    Cytotoxicity of compound was tested against Molt-4 cell line (T-cell leukemia) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    MOLT-4 IC50
    1.0 x 10-9 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against Molt-4 cell line (T-cell leukemia) after incubation for 24 hour
    Cytotoxicity of compound was tested against Molt-4 cell line (T-cell leukemia) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    NHDF IC50
    4.04 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against NHDF cell line (norm human dermal fibroblast) after incubation for 72 hour
    Cytotoxicity of compound was tested against NHDF cell line (norm human dermal fibroblast) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    NHDF IC50
    3.9 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against NHDF cell line (norm human dermal fibroblast) after incubation for 24 hour
    Cytotoxicity of compound was tested against NHDF cell line (norm human dermal fibroblast) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    OVCAR-3 IC50
    2.87 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against Ovcar-3 cell line (ovarian carcinoma) after incubation for 72 hour
    Cytotoxicity of compound was tested against Ovcar-3 cell line (ovarian carcinoma) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    OVCAR-3 IC50
    3.9 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against Ovcar-3 cell line (ovarian carcinoma) after incubation for 24 hour
    Cytotoxicity of compound was tested against Ovcar-3 cell line (ovarian carcinoma) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    P388 IC50
    3 nM
    Compound: Daunorubicin HCl
    Growth Inhibition of P388/0 cell lines.
    Growth Inhibition of P388/0 cell lines.
    		[PMID: 10669575]
    P388 IC50
    < 9.8 x 10-8 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against P-388 cell line (mouse leukemia) after incubation for 72 hour
    Cytotoxicity of compound was tested against P-388 cell line (mouse leukemia) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    P388 IC50
    3.9 x 10-7 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against P-388 cell line (mouse leukemia) after incubation for 24 hour
    Cytotoxicity of compound was tested against P-388 cell line (mouse leukemia) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    PC-3 IC50
    0.23 μg/mL
    Compound: Daunorubicin HCl
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 12141872]
    PC-3 IC50
    0.44 μM
    Compound: Daunorubicin
    Cytotoxicity against human PC-3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells after 48 hrs by MTT assay
    		[PMID: 17190447]
    SK-MEL-28 IC50
    1.41 x 10-6 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against SK-Mel-28 cell line (melanoma) after incubation for 72 hour
    Cytotoxicity of compound was tested against SK-Mel-28 cell line (melanoma) after incubation for 72 hour
    		10.1016/S0960-894X(00)80285-1
    SK-MEL-28 IC50
    1.6 x 10-6 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against SK-Mel-28 cell line (melanoma) after incubation for 24 hour
    Cytotoxicity of compound was tested against SK-Mel-28 cell line (melanoma) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    SW-620 IC50
    8.6 μM
    Compound: DNR hydrochloride
    Cytotoxicity against SW620 colon cancer cell line done for 72 h at 37 degree C with compound in MTS assay
    Cytotoxicity against SW620 colon cancer cell line done for 72 h at 37 degree C with compound in MTS assay
    		[PMID: 16078845]
    T-24 IC50
    2 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against bladder carcinoma (T-24) human tumor cells
    Antiproliferative activity of compound was tested against bladder carcinoma (T-24) human tumor cells
    		10.1016/0960-894X(95)00523-3
    UCLA P-3 IC50
    7.3 x 10-3 M
    Compound: 1 (Daunomycin hydrochloride)
    Cytotoxicity of compound was tested against UCLA P-3 cell line (lung carcinoma) after incubation for 24 hour
    Cytotoxicity of compound was tested against UCLA P-3 cell line (lung carcinoma) after incubation for 24 hour
    		10.1016/S0960-894X(00)80285-1
    WiDr IC50
    7 μM
    Compound: Daunomycin
    Antiproliferative activity of compound was tested against colon carcinoma (WiDr) human tumor cells
    Antiproliferative activity of compound was tested against colon carcinoma (WiDr) human tumor cells
    		10.1016/0960-894X(95)00523-3
    In Vitro

    Daunorubicin hydrochloride (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells[2].
    Daunorubicin hydrochloride (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells[3][4].
    Daunorubicin hydrochloride (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells[4].
    Daunorubicin hydrochloride (0.4 μM, 120 min) induces ROS generation in L3.6 cells[4].
    Daunorubicin hydrochloride (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Daunorubicin hydrochloride Related Antibodies

    Cell Viability Assay[3][4]

    Cell Line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
    Concentration: 7 nM-1.9 μM
    Incubation Time: 72 h
    Result: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6).

    Apoptosis Analysis[4]

    Cell Line: L3.6 cells
    Concentration: 0.4 μM
    Incubation Time: 72 h
    Result: Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h.

    Western Blot Analysis[6]:

    Cell Line: K562 cells
    Concentration: 2 μM
    Incubation Time: 24 h
    Result: Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.
    In Vivo

    Daunorubicin hydrochloride (intravenous injection, 3 mg/kg, three times at 48 h intervals.) produces cardiotoxicity and nephrotoxicity in rats[5].
    Daunorubicin hydrochloride (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Sprague-Dawley rats[5]
    Dosage: 3 mg/kg
    Administration: Intravenous injection, three times at 48 h intervals.
    Result: Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity.
    Increased urinary protein excretion, serum creatinine, and BUN level.
    분자량

    563.98

    화학식

    C27H30ClNO10
    CAS No.
    Appearance

    Solid

    Color

    Pink to red

    SMILES

    O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O.[H]Cl
    Structure Classification
    Initial Source

    Streptomyces coeruleorubidus
    선적

    Room temperature in continental US; may vary elsewhere.
    보관

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    용액&용해도
    In Vitro: 

    DMSO : 50 mg/mL (88.66 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : ≥ 34 mg/mL (60.29 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7731 mL 8.8656 mL 17.7311 mL
    5 mM 0.3546 mL 1.7731 mL 3.5462 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • 몰농도 계산기

    • 농도 희석 계산기

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (3.69 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 33.33 mg/mL (59.10 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    순도&문서

    Purity: 99.67%

    SDS (644 KB)

    COA (258 KB) HNMR (135 KB) LCMS (93 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 1.7731 mL 8.8656 mL 17.7311 mL 44.3278 mL
    5 mM 0.3546 mL 1.7731 mL 3.5462 mL 8.8656 mL
    10 mM 0.1773 mL 0.8866 mL 1.7731 mL 4.4328 mL
    15 mM 0.1182 mL 0.5910 mL 1.1821 mL 2.9552 mL
    20 mM 0.0887 mL 0.4433 mL 0.8866 mL 2.2164 mL
    25 mM 0.0709 mL 0.3546 mL 0.7092 mL 1.7731 mL
    30 mM 0.0591 mL 0.2955 mL 0.5910 mL 1.4776 mL
    40 mM 0.0443 mL 0.2216 mL 0.4433 mL 1.1082 mL
    50 mM 0.0355 mL 0.1773 mL 0.3546 mL 0.8866 mL
    60 mM 0.0296 mL 0.1478 mL 0.2955 mL 0.7388 mL
    DMSO 80 mM 0.0222 mL 0.1108 mL 0.2216 mL 0.5541 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Daunorubicin hydrochloride Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Daunorubicin23541-50-6DaunomycinRP 13057RubidomycinRP13057RP-13057TopoisomeraseDNA/RNA SynthesisADC PayloadBacterialAutophagyApoptosisAntibioticADC CytotoxinAnti-tumorEhrlich ascites tumorpancreatic carcinoma leukemiacytotoxinMolt-4 cellL3.6 cellK562 cellschamomileInhibitorinhibitorinhibit

    최근 본 상품:

    온라인 문의

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Requested Quantity *

    고객명 *

    		 

    호칭

    메일주소 *

    		 

    전화번호 *

    Department

    		 

    회사명 *

    City

    도

    Country or Region *

    		      

    비고

    대량구매 문의

    Inquiry Information

    상품명:
    Daunorubicin hydrochloride
    Cat. No.:
    HY-13062
    수량:
    MCE Japan Authorized Agent:

    고객리뷰

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Lot #

    고객명 *

    		 

    메일주소 *

    전화번호

    		 

    Department *

    회사명 *

    		 

    Country or Region *

    비고

    SAFETY DATA SHEET (SDS)

    English - EN (644 KB) Français - FR (644 KB) Deutsch - DE (644 KB) Norwegian - NO (644 KB) Español - ES (644 KB) Swedish - SV (644 KB) Italian - IT (644 KB) Korean - KR (644 KB) Portuguese - PT (644 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.